newsfilter
← Latest News
GlobeNewswire·

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented additional analyses